These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 8949719

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications.
    Pagliara MM, Tagliaferri L, Azario L, Lenkowicz J, Lanza A, Autorino R, Caputo CG, Gambacorta MA, Valentini V, Blasi MA.
    Brachytherapy; 2018; 17(2):432-438. PubMed ID: 29275868
    [Abstract] [Full Text] [Related]

  • 4. Tumor parameters predict the risk of side effects after ruthenium-106 plaque brachytherapy of uveal melanomas.
    Tarmann L, Wackernagel W, Ivastinovic D, Schneider M, Winkler P, Langmann G.
    PLoS One; 2017; 12(8):e0183833. PubMed ID: 28859118
    [Abstract] [Full Text] [Related]

  • 5. Visual outcome of eyes with malignant melanoma of the uvea after ruthenium plaque radiotherapy.
    Summanen P, Immonen I, Kivelä T, Tommila P, Heikkonen J, Tarkkanen A.
    Ophthalmic Surg Lasers; 1995; 26(5):449-60. PubMed ID: 8963860
    [Abstract] [Full Text] [Related]

  • 6. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients.
    Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, Freire J.
    Ophthalmology; 2002 Oct; 109(10):1838-49. PubMed ID: 12359604
    [Abstract] [Full Text] [Related]

  • 7. [The analysis of I125 brachytherapy complications in cases of uveal melanoma].
    Pogrzebielski A, Starzycka M, Romanowska-Dixon B, Jakubowska B, Szpakowicz U.
    Klin Oczna; 2005 Oct; 107(1-3):49-53. PubMed ID: 16052800
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
    Rouberol F, Roy P, Kodjikian L, Gérard JP, Jean-Louis B, Grange JD.
    Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
    [Abstract] [Full Text] [Related]

  • 10. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
    Razzaq L, Keunen JE, Schalij-Delfos NE, Creutzberg CL, Ketelaars M, de Keizer RJ.
    Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
    [Abstract] [Full Text] [Related]

  • 11. [Long-term results of cobalt 60 curietherapy for uveal melanoma].
    Bacin F, Kwiatkowski F, Dalens H, Rozan R, Gagyi S, Donnarieix D, Bard JJ, Robert JL.
    J Fr Ophtalmol; 1998 May; 21(5):333-44. PubMed ID: 9759427
    [Abstract] [Full Text] [Related]

  • 12. [Retrospective analysis of ruthenium-106 brachytherapy for small and medium-sized malignant melanoma of the posterior choroid].
    Stoffelns BM, Kutzner J, Jochem T.
    Klin Monbl Augenheilkd; 2002 Apr; 219(4):216-20. PubMed ID: 12022004
    [Abstract] [Full Text] [Related]

  • 13. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
    Puusaari I, Heikkonen J, Kivelä T.
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
    [Abstract] [Full Text] [Related]

  • 14. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
    Kaiserman N, Kaiserman I, Hendler K, Frenkel S, Pe'er J.
    Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
    Böker A, Pilger D, Cordini D, Seibel I, Riechardt AI, Joussen AM, Bechrakis NE.
    Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
    [Abstract] [Full Text] [Related]

  • 16. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.
    Krohn J, Monge OR, Skorpen TN, Mørk SJ, Dahl O.
    Eye (Lond); 2008 Nov; 22(11):1398-403. PubMed ID: 17585309
    [Abstract] [Full Text] [Related]

  • 17. Ruthenium-106 plaque brachytherapy for uveal melanoma.
    Tarmann L, Wackernagel W, Avian A, Mayer C, Schneider M, Winkler P, Langmann G.
    Br J Ophthalmol; 2015 Dec; 99(12):1644-9. PubMed ID: 25979763
    [Abstract] [Full Text] [Related]

  • 18. Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.
    Takiar V, Gombos DS, Mourtada F, Rechner LA, Lawyer AA, Morrison WH, Garden AS, Beadle BM.
    Pract Radiat Oncol; 2014 Dec; 4(4):e189-94. PubMed ID: 25012839
    [Abstract] [Full Text] [Related]

  • 19. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.
    Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW.
    Arch Ophthalmol; 1999 Feb; 117(2):170-7. PubMed ID: 10037560
    [Abstract] [Full Text] [Related]

  • 20. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients.
    Shields CL, Shields JA, Cater J, Gündüz K, Miyamoto C, Micaily B, Brady LW.
    Arch Ophthalmol; 2000 Sep; 118(9):1219-28. PubMed ID: 10980767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.